Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Trial · NCT04745832
Adverse events352
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 352
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Rituximab Plus Zandelisib | 1 | 41 | |
| other | Anaemia | Blood and lymphatic system disorders | Rituximab Plus Chemotherapy | 4 | 41 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Rituximab Plus Zandelisib | 0 | 41 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Rituximab Plus Chemotherapy | 2 | 41 | |
| other | Neutropenia | Blood and lymphatic system disorders | Rituximab Plus Zandelisib | 2 | 41 | |
| other | Neutropenia | Blood and lymphatic system disorders | Rituximab Plus Chemotherapy | 1 | 41 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Rituximab Plus Zandelisib | 0 | 41 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Rituximab Plus Chemotherapy | 2 | 41 | |
| other | Palpitations | Cardiac disorders | Rituximab Plus Zandelisib | 0 | 41 | |
| other | Palpitations | Cardiac disorders | Rituximab Plus Chemotherapy | 1 | 41 | |
| other | Supraventricular extrasystoles | Cardiac disorders | Rituximab Plus Zandelisib | 1 | 41 | |
| other | Supraventricular extrasystoles | Cardiac disorders | Rituximab Plus Chemotherapy | 0 | 41 | |
| other | Supraventricular tachycardia | Cardiac disorders | Rituximab Plus Zandelisib | 0 | 41 | |
| other | Supraventricular tachycardia | Cardiac disorders | Rituximab Plus Chemotherapy | 1 | 41 | |
| other | Hypoacusis | Ear and labyrinth disorders | Rituximab Plus Zandelisib | 0 | 41 | |
| other | Hypoacusis | Ear and labyrinth disorders | Rituximab Plus Chemotherapy | 1 | 41 | |
| other | Vertigo | Ear and labyrinth disorders | Rituximab Plus Zandelisib | 0 | 41 | |
| other | Vertigo | Ear and labyrinth disorders | Rituximab Plus Chemotherapy | 1 | 41 | |
| other | Vertigo positional | Ear and labyrinth disorders | Rituximab Plus Zandelisib | 0 | 41 | |
| other | Vertigo positional | Ear and labyrinth disorders | Rituximab Plus Chemotherapy | 1 | 41 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04745832/events